Nervous Disorder TRIZ Cases

Fibronectin coating and optimized media increase stem cell proliferation rates, resolving low efficiency in stored samples.

Bispecific antibodies anchor at tissue via LOXL2 binding to capture local CCL2, reducing systemic waste and improving therapeutic efficacy.

Eslicarbazepine acetate avoids GABAA receptor enhancement that aggravates absence seizures while maintaining sodium channel blocking activity.

Ethosome vesicles encapsulate magnesium and capsaicin to enhance transdermal delivery, reducing burning sensation while maintaining therapeutic efficacy.

Specific amino acid substitutions in metastin derivatives improve blood stability and pharmacokinetics while maintaining cancer metastasis suppression.

Nasal formulation bypasses first-pass metabolism to deliver anticonvulsant directly to brain, resolving low bioavailability.

A fusion protein combines a transcription modulating domain with a protein transduction domain for intracellular delivery.

Nefopam reduces opioid dependency and gastrointestinal risks while maintaining reliable pain relief in sickle cell disease.

Isolated microbes increase butyrate production to modulate the nervous system.

Anti-nerve growth factor antibodies block signaling pathways to reduce ongoing and movement-evoked bone cancer pain without opioid side effects.

Adeno-associated viral vectors deliver NeuroD1 and Dlx2 nucleic acids to trigger striatal glial cells into forming functional GABAergic neurons.

Intranasal CXCR4 antagonistic peptides bypass metabolic degradation to treat central nervous system disorders.

Orbital shaking suppresses TNF-alpha while boosting TSG-6 expression in adipose tissue, resolving chemical digestion trade-offs.

Targeted peptide sequences activate cytotoxic T lymphocytes against hepatocellular carcinoma, bypassing chemotherapeutic resistance mechanisms.

HSA-free interferon-beta formulation prevents aggregation and oxidation using Pluronic surfactants and methionine to maintain biological activity.

Anti-BAG3 antibodies bind soluble extracellular BAG3 protein to impair tumor cell development, reducing pancreatic tumor growth by over 75%.

A doxycycline-regulated vector enables reversible GDNF expression in neural progenitor cells.

Antibodies bind specific alpha-synuclein epitopes to trigger immune clearance of Lewy bodies, addressing ineffective neurodegenerative treatments.

Integrin alpha10beta1 surface expression resolves low specificity of intracellular markers, enabling high-purity neural stem cell isolation.

A dosage regimen initiates S1P receptor agonist treatment at a reduced daily level before gradual escalation to standard therapeutic doses.

Anti-SIRPα antibodies disrupt the SIRPα-CD47 interaction to enhance tumor clearance while minimizing off-target toxicity.

The peptide Pro-Ala-Tyr-Cys-Ser regulates intestinal flora and brain neurotransmitters to address memory impairment.

Antibody 3.2.52 binds Aβ42 with high affinity, resolving rheumatoid factor interference in blood assays.

A fermented composite of Gastrodia elata, black rice, and wheat seedlings elevates brain dopamine levels through multi-stage probiotic processing.

An ABC transporter inhibitor blocks efflux pumps to increase riluzole concentrations in the central nervous system, overcoming blood-brain barrier limitations.

Humanized anti-human NGF antibody blocks receptor binding to resolve pain relief versus side effect trade-offs.

Specific amino acid modifications in CDR regions enhance binding affinity to Aβ monomers, reducing immunogenicity while maintaining therapeutic efficacy.

Amorphous rifaximin dispersion with hydrogenated castor oil enhances gastrointestinal solubility.

Co-expressing NPY and NPY2R via a single rAAV vector prevents receptor downregulation, sustaining anti-seizure effects in pharmacoresistant epilepsy.

A composition containing black rice and cherry blossom extracts normalizes endometrial epithelial cell phenotypes to alleviate menstrual discomfort.

Birch sap extract mediates seizure control alongside conventional drugs, lowering side effect severity while maintaining reliability.

Peripheral antibody administration resolves the trade-off between efficacy and invasiveness.

IL-2 mutein fused with IgG1 Fc region expands regulatory T cells while resolving serum half-life and immunogenicity constraints.

Antagonist antibodies inhibit ALK7 receptors to resolve modest weight loss in obesity treatments.

Increasing CPAR levels in the nucleus accumbens addresses pain-induced depression without relying on traditional analgesics that cause significant side effects.

A collaborative system dynamically adjusts video detail and frame rate to maintain session quality.

Akkermansia bacteria restore reward system function by modulating gut-brain axis communication to treat neuroinflammation.

Segmented XIST A-repeat minigenes deliver localized gene silencing up to 5 Mb from insertion sites, avoiding chromosome-wide repression.

Fomes fomentarius extract treats dementia by inhibiting inflammatory cytokines and improving brain glucose metabolism without gastrointestinal side effects.

Benedin piperidine derivative targets muscarinic M1, M2, and M3 receptors to resolve ineffective short-term relief in Kleine-Levin syndrome treatment.

Neutral 7-phenyl-2-aminoquinoline structures enhance blood-brain barrier permeation and selectivity over other NOS isoforms.

Therapeutic peptides reduce free fatty acid levels through targeted amino acid substitutions.

Converting L-alanine to levomethadone hydrochloride via preliminary action eliminates resolution steps, boosting yield above 40% while maintaining purity.

Nervous system-specific delivery vectors express deoxyribonuclease enzymes to clear microbial and viral cell-free DNA from cerebrospinal fluid.